NCT03349892View on ClinicalTrials.gov

Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia

NACompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

August 6, 2019

Study Completion Date

August 6, 2019

Conditions
Refractory Ventricular Tachycardia
Interventions
RADIATION

Stereotactic Ablative Radiotherapy (SABR)

A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.

Trial Locations (1)

90095-6951

UCLA Department of Radiation Oncology, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT03349892 - Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia | Biotech Hunter | Biotech Hunter